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Purpose of the study
To estimate the short-term probability of treatment
change in antiretroviral naïve patients receiving tenofo-
vir (TDF), emtricitabine (FTC) and efavirenz (EFV) as a
one (1p) or two pills (2p) regimen.
Methods
We evaluated, by logistic regression and Cox propor-
tional model analysis, factors associated to treatment
modification during the first year of HAART in antire-
troviral naïve patients from a single HIV unit in Madrid
who started treatment with TDF, FTC and EFV as 1 p
or 2p. For this analysis we censored patients who
switched from 2p to 1p.
Results
From Jan/06 to Dec/09, 136 patients started HAART with
T D F ,F T C&E F Va s1 p( 5 9 ,4 2 . 8 % )o r2 p( 7 9 ,5 7 . 2 % ) .M e a n
age: 38.5 (1p) and 38.6 (2p), 83.1% male (1p) and 75.3% (2p).
Median CD4: 250 (1p) and 244 (2p), mean viral load (log):
4.53 (1p) and 4.48 (2p), HCV coinfected: 15.3% (1p) and
19.5% (2p). One-year probability of HAART modification
was 14.7% (95%CI 9.7-21.6) globally, 20.78% (13.22-31.12)
for 2p and 6.7% (2.67-16.18) for 1p. Proportions of patients
with viral load <50 copies/mL after one year of follow up
were 87.5% (1p) and 94.4% (2p). Reasons for HAART modi-
fication were toxicity (8.7%) and lack of efficacy (2.2%) or
adherence (3.6%). HAART modification due to toxicity was
more frequent (7.52%) with 2p (5 skin rashes, 2 SNC adverse
events, 1 impairment of renal function and 1 osteopenia)
than with 1p (2 skin rashes, 1.5%). Patients on 2p were
changed to TDF/FTC + LPV/r (3), TDF/FTC + ATV/r (2),
TDF/FTC + NVP (1), ABC/3TC + EFV (2), ABC/3TC +
LPV/r (1), ABC/3TC + ATV/r (1), AZT/3TC/ABC + TDF
(1) or stopped treatment (5). Patients on 1p switched to
TDF/FTC + LPV/r (1), TDF/FTC + DRV/r (1) or stopped
treatment (2). Multivariant logistic regression analysis
showed that a 2p regimen [OR 5.0 (1.18-21.16)], prior
AIDS-defining condition [4.09 (1.37-12.27)] and time
(months) since HIV diagnosis [1.015 (1.006-1.025)] were sig-
nificantly associated to HAART modification.
Conclusions
Our study suggests that patients receiving TDF, FTC and
EFV as 1p are more likely to maintain the regimen after
one year than patients receiving the same regimen as 2p.
Reasons for this difference might be related to a higher
threshold for both clinicians and patients to change ther-
apy even in the context of adverse events when patients
are receiving TDF, FTC and EFV as a single pill.
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